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Kinetics of Nebivolol and its Active Metabolite After Single
Dose Oral Administration of Nebivolol
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Biopharmaceutics, 8 Victor Babes Str., 400012, Cluj-Napoca, Romania
2 University of Bonn Medical Center, Institute of Neuropathology, 25 D Sigmund Freud, 53127, Bonn, Germany
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A pharmacokinetic study of nebivolol and its active metabolite (4-hydroxy-nebivolol) after single dose oral
administration of nebivolol to 20 healthy volunteers was realized. The representative pharmacokinetic model
involves first order absorption kinetics for nebivolol with pre-systemic metabolism, first order systemic
metabolism and bicompartmental distribution for nebivolol and its metabolite. By using this model, the
most important pharmacokinetic parameters were further calculated.
Keywords: nebivolol, 4-hydroxy-nebivolol, compartmental pharmacokinetic analysis
Nebivolol   is  a  third  generation,  highly - selective
beta1-blocker, also having a vasodilatatory effect due to
enhancing nitric oxide bioavailability via the L-arginine-
nitric oxide pathway [1-3]. This unique characteristic
among beta-blockers can offer a supplementary benefit in
hypertension treatment besides lowering the blood
pressure per se, being well-known the protective action of
nitric-oxide against cardio-vascular risk factors, mainly
atherosclerosis [4, 5]. At therapeutic doses (5 mg once a
day for adults), nebivolol is considered a safe drug, with a
relative low incidence of adverse reactions. Despite its
therapeutic benefit, nebivolol has some important side
effects that arise in intensity in relation with the drug plasma
levels. The most important adverse reactions are
paraesthesia, bradycardia, AV block, acute cardiac failure,
hypotension, dizziness, fatigue, edema or headache [6, 7].
Pharmacokinetics, by the quantitative study of the
processes that take place depending on time [8, 9], during
the stages of absorption, distribution, metabolism and
excretion of a drug, offers a better understanding of the
relationship between the given/administered dose and the
pharmacological effect [10]. By using compartmental and
non-compartmental analysis, the corresponding
pharmacokinetic parameters of the drug can be obtained,
and it can be used in drug formulation, bioequivalence or
in therapeutic drug monitoring for patient-specific dose
adjustment.
The aim of this study was to create and to use a
pharmacokinetic model that can accurately describe the
kinetic processes involved in absorption, distribution,
metabolism and elimination of nebivolol and 4-hydroxy-
nebivolol after oral administration of a single dose of
nebivolol in healthy volunteers.
Experimental part
Materials and methods
Subjects
A number of 20 healthy volunteers were enrolled in the
study. The study was conducted according to principles of
Declaration of Helsinki (1964) and its amendments (Tokyo
1975, Venice 1983, Hong Kong 1989). The clinical protocol
was reviewed and approved by the Ethics Committee of
the University of Medicine and Pharmacy Iuliu Hatieganu,
Cluj-Napoca.
Study protocol
After an overnight fast the volunteers received a single 5
mg nebivolol dose (Nebilet 5 mg tablets, Berlin-Chemie
AG, Germany) at 8:00 a.m. along with 150 mL of water.
Blood samples (5 mL) were taken via an indwelling venous
cannula according to the following time schedule: before
drug administration (0 h), and 0.5, 1, 1.5, 2, 2.5, 3, 4, 6, 8,
10, 12, 24, 36 and 48 h after drug administration. Within 10
minutes of collection, blood samples were centrifuged at
5000 rpm for 10 min and plasma samples were stored  at
-20oC until analysis.
Drug analysis from plasma
Nebivolol and its corresponding hydroxylated metabolite
(4-hydroxy-nebivolol) plasma concentrations were
determined by a validated liquid chromatography–mass
spectrometry method [11]. The HPLC system was an
Agilent 1100 series (binar y pump, autosampler,
thermostat) (Agilent Technologies, USA) and was coupled
with a Bruker Ion Trap SL (Bruker Daltonics GmbH,
Germany). A Zorbax SB-C18 chromatographic column (100
mm x 3.0 mm i.d., 3.5µm) (Agilent Technologies) was
used. The mobile phase consisted of 0.2% (V/V) formic
acid in water and acetonitrile, and gradient elution was as
follows: start with 10% acetonitrile, at 6.6 min 43%
acetonitrile. The flow rate was 1 mL/min, and the
thermostat temperature was set at 48°C. The mass
spectrometr y detection was in multiple reaction
monitoring mode, positive ions, using an electrospray
ionization source. The ion transitions monitored were m/z
406 for nebivolol (single ion monitoring mode) and m/z
404 from m/z 422 for its hydroxylated metabolite (multiple
ion monitoring mode). The sample preparation was
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Table 1
PHARMACOKINETIC MODELS
OF NEBIVOLOL AND ITS ACTIVE
METABOLITE USED IN
COMPARTMENTAL ANALYSIS.
Fig. 1. Schematic representation of kinetic processes from model
M6, where 0 is absorption compartment of nebivolol; 1 and 2 are
central compartments of nebivolol and 4-hydroxy-nebivolol; 3 and 4
are their corresponding peripheral distribution compartments; tlag
is the latency time for absorption; k01 is the absorption rate
constant of nebivolol, f is the fraction of nebivolol converted into
metabolite during absorption (presystemic metabolism); k13, k31,
k24, k42 are the distribution rate constants; k12 is the systemic
metabolisation rate constant of nebivolol to metabolite; k10 and k20
are the elimination rate constants for nebivolol (non-metabolic) and
4-hydroxy-nebivolol
performed by adding 0.6 mL methanol to 0.2 mL plasma
in an Eppendorf tube. The tube was vortexed for 10 s, then
centrifuged for 6 min at 7425 g. The supernatant was
transferred to an autosampler vial, and 40 µL was injected
into the chromatographic system. The calibration curves
of nebivolol and its active metabolite (4-hydroxy-nebivolol)
were linear at a concentration range of 0.1–16 ng/mL
plasma.
Pharmacokinetic analysis
The compartmental pharmacokinetic analysis was
employed for analysis of plasma versus time levels of
nebivolol and its metabolite for each individual dataset
obtained from the volunteers (20 datasets).
Six mathematical models were created in order to
analyse the pharmacokinetics of nebivolol and its active
metabolite (table 1).
The differences between the models consisted in
assumptions about the existence of presystemic
metabolism of nebivolol and about the number of
compartments for both nebivolol and 4-hydroxy-nebivolol.
For example, the first pharmacokinetic model employs no
presystemic metabolism of nebivolol and mono-
compartmental distribution for both nebivolol and its
metabolite. The model MC6 employs existence of
presystemic metabolism and bicompartmental distribution
for both nebivolol and 4-hydroxy-nebivolol. Each model
considers that the elimination of compounds is a 1st order
kinetic process, as well as the systemic metabolism of
nebivolol to 4-hydroxy-nebivolol.
The schematic representation of the kinetic processes
from model M6 are presented in figure 1.
For each kinetic model, the corresponding
mathematical differential equations were written and run
by using Phoenix 6.1 software package (Certara, SUA).
The equations of model M6 are presented in figure 2.
Fig. 2.The mathematical equations of the kinetic model
M6, where QNC and QNP are the quantities of nebivolol in
central and peripheral compartment respectively; QMC
and QMP are the quantities of metabolite in central and
peripheral compartments; ConcN and ConcM are the
plasma concentrations of nebivolol and 4-hydroxy-
nebivolol, V_F is the apparent volume of distribution of
the central compartment. All the other parameters used
were previously presented
REV.CHIM.(Bucharest)♦67♦No.4 ♦2016http://www.revistadechimie.ro
Results and discussions
The mean plasma concentrations of nebivolol and 4-
hydroxy-nebivolol were analysed using the six kinetic
models previously presented, after their implementation
in Phoenix software. The same settings of the software
minimisation engine were used for all analysed models:
weighting scheme 1/y (1/observed concentration),
minimisation method: Gauss-Newton (Levenberg and
Hartley variant), convergence criterion: 0.0001.
The Akaike index (automatically calculated and
provided by the analysis software) was used for model
discrimination [12]. The model that fit better to the data is
characterised by a smaller Akaike index. The Akaike values
for the six analysed models are presented in figure 3.
By analysing the Akaike values presented in figure  3,
one can see that the model M6 fits the data better than its
concurrent models, having the smallest Akaike value, so it
was chosen as representative for describing the kinetics
of nebivolol and 4-hydroxy-nebivolol after oral
administration of a single dose of nebivolol.
In  figure   4 is presented a typical fitting of a subject data
to representative model M6 in comparison with M1. There
is a better correlation between the experimental
(observed) and the fitted (predicted) values for nebivolol
and 4–hydroxy-nebivolol concentrations in case of the
model M6 than in case of the model M1.
According to the M6, the pharmacokinetics of nebivolol
is characterised by a first order absorption rate kinetics
with presystemic metabolism to 4–hydroxy-nebivolol. Both
nebivolol and 4–hydroxy-nebivolol are characterised by
bicompartmental distribution. After absorption, nebivolol
is converted to 4–hydroxy-nebivolol by systemic
metabolism, following a first-order kinetic process. Both
compounds are further eliminated from the body by first
order kinetic processes. By using this representative
pharmacokinetic model for nebivolol and 4–hydroxy-
nebivolol, their characteristic pharmacokinetic parameters
were calculated (table 2).
A large variability of calculated kinetic parameters of
nebivolol and its metabolite can be observed between the
Fig. 3. Akaike index values for mathematical models used for
characterisation of nebivolol and 4-hydroxy-nebivolol
kinetics
Fig. 4. Typical fitting of model M1 (left)
and model M6 (right) to a subject data
(o and! denote the experimental
determined concentrations of nebivolol
and its metabolite, respectively; the
continues and dotted lines are the
fitted/computed concentrations
predicted by the kinetic model)
20 subjects participating in the study (table 2). However,
this is commonly seen in such studies due to natural biologic
and physiologic differences between subjects (inter-
subject variability) [13, 14].
The absorption of nebivolol is delayed for about
0.30±0.23 h after oral administration, the time needed for
drug to reach into duodenum. The absorption rate constant
is 2.60±2.72 h-1, that means an absorption half-life of about
0.266 h During absorption, about 10% of the bio-available
amount of nebivolol is converted to metabolite that appears
in plasma.
The apparent volume of distribution for central
compartment of both nebivolol and metabolite is about
1410±903 L, this high value being expected as both
compounds are lipophilic and highly bounded on tissue
proteins [1]. The kinetic model M6 considers for nebivolol
two elimination paths: by systemic metabolism to 4–
hydroxy-nebivolol (characterised by a rate constant k12)
and by other processes (characterised by an overall rate
constant k10). As can be observed from table 2, the value
of k12 (0.318±0.208 h-1) is much higher than k10 (5.53 .
10-4±6.23 . 10-4 h-1). This means that a large majority of
99.8% from nebivolol is eliminated from the body by
metabolisation to 4–hydroxy-nebivolol, the rest being
eliminated by metabolisation to other metabolites or by
direct renal excretion. Both nebivolol and its metabolite
are distributed between central and peripheral
compartments, the last having a greater affinity for each
compound (k13>k31 and k24>k42).
The observed concentrations of 4–hydroxy-nebivolol are
due to both presystemic and systemic biotransformation
of nebivolol. The metabolite is eliminated following a first-
order kinetic process, characterised by a rate constant of
0.332±0.305 h-1.
Conclusions
In order to describe the kinetics of nebivolol and its
metabolite 4–hydroxy-nebivolol after oral administration
of a single oral dose of 5 mg nebivolol, six mathematical
models were tested. These models involve differences
704
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regarding the presystemic metabolisation of nebivolol to
its metabolite and the mono- or bicompartmental
distribution of the compounds.
After data analysis, the representative model for the
pharmacokinetics of nebivolol and its metabolite was
assessed. This model considers that nebivolol is absorbed
following a first-order process and is partially converted
during absorption to the metabolite. The kinetics of
nebivolol is characterised by bicompartmental distribution
and first order kinetic elimination processes (99.8% by
biotranformation to metabolite, the rest by other paths).
The metabolite 4–hydroxy-nebivolol has also a
bicompartmental distribution and a first order elimination
kinetics.
The knowledge of the drug kinetics in the body (e.g. the
kinetic model) is the starting point for other important
analysis like the prediction of drug plasma levels at other
doses or when multiple doses are administered,
pharmacokinetic population modelling or further
mathematical correlations between drug kinetics and the
pharmacological effect intensity.
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